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BACKGROUND. Family history is a major risk factor for prostate cancer (PCa), suggesting a
genetic component to the disease. However, traditional linkage and association studies have
failed to fully elucidate the underlying genetic basis of familial PCa.
METHODS. Here, we use a candidate gene approach to identify potential PCa susceptibility
variants in whole exome sequencing data from familial PCa cases. Six hundred ninety-seven
candidate genes were identified based on function, location near a known chromosome 17
linkage signal, and/or previous association with prostate or other cancers. Single nucleotide
variants (SNVs) in these candidate genes were identified in whole exome sequence data from
33 PCa cases from 11 multiplex PCa families (3 cases/family).
RESULTS. Overall, 4,856 candidate gene SNVs were identified, including 1,052 missense and
10 nonsense variants. Twenty missense variants were shared by all three family members in
each family in which they were observed. Additionally, 15 missense variants were shared by
two of three family members and predicted to be deleterious by five different algorithms. Four
missense variants, BLM Gln123Arg, PARP2 Arg283Gln, LRCC46 Ala295Thr and KIF2B
Pro91Leu, and one nonsense variant, CYP3A43 Arg441Ter, showed complete co-segregation
with PCa status. Twelve additional variants displayed partial co-segregation with PCa.
CONCLUSIONS. Forty-three nonsense and shared, missense variants were identified in our
candidate genes. Further research is needed to determine the contribution of these variants to
PCa susceptibility. Prostate 74:1371–1378, 2014. # 2014 Wiley Periodicals, Inc.
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INTRODUCTION
Prostate cancer (PCa) is the most commonly diag-
nosed cancer and the second leading cause of cancer
deaths among American men [1]. Positive family
history is one of the most recognized risk factors for
PCa diagnosis, suggesting a genetic component to the
disease [2]. However, the genetic basis of PCa is still
poorly understood. Linkage studies focused on heredi-
tary PCa pedigrees have provided inconsistent results.
Genome-wide association studies of large case-control
cohorts have identified dozens of single nucleotide
variants (SNVs) which are consistently associated with
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PCa [3]. However, the risk elevation attributed to each
of these variants is low (<1.3 per SNV), and together,
they account for less than one quarter of familial PCa
risk [4]. Targeted sequencing of a candidate linkage
region on chromosome 17q21-22 led to the recent
identification of the first rare, penetrant PCa suscepti-
bility gene, HOXB13 with the G84E mutation resulting
in a 10- to 20-fold increased risk of PCa [5]. Taken
together, PCa is likely a highly genetically heteroge-
neous disease, with rare PCa susceptibility variants
yet to be discovered.
Massively parallel sequencing technologies now
provide the ability to interrogate large amounts of
genomic DNA, including entire genes and/or exomes,
and to comprehensively catalog rare DNAvariation on
an individual basis. Here, we use a candidate gene
approach to analyze whole exome sequencing data
from 33 men with PCa in 11 unrelated hereditary PCa
pedigrees to identify new PCa risk variants.
MATERIALSANDMETHODS
Patient Selection
All individuals/families are participants in the
University of Michigan Prostate Cancer Genetics Proj-
ect (UM PCGP). Eleven pedigrees, each with three or
more confirmed affected individuals, including at least
one distant affected relative pair (e.g., cousins or an
avuncular pair), were selected for whole exome se-
quencing. Germline DNA from three men with PCa
per family was sequenced. Selection of the cases for
sequencing in each pedigree was based on earliest age
of PCa diagnosis with some preference given to
aggressive cases. Genomic DNA was prepared using
standard protocols. PCa diagnoses were confirmed by
medical record review and reports were received from
all cases selected for sequencing. Some additional
cases were confirmed by two independent family
members when records were not retrievable. Written
informed consent was obtained from all subjects, and
the research project was approved by the University of
Michigan Institutional Review Board.
Exome Sequencing
Exome capture was performed with a SureSelectXT
Human All Exon 50mB kit (Agilent Technologies,
Santa Clara, CA). Enriched libraries were then sequ-
enced on an Illumina HiSeq2000 (Illumina, Inc., San
Diego, CA). Sequence data was aligned to the reference
sequence using the Burrows–Wheeler Aligner
(BWA) [6], and variant calls were made using The
Genome Analysis Tool Kit (GATK) [7]. Called variants
were then annotated using ANNOVAR [8] which
included classification of variants as benign/non-con-
served or deleterious/conserved by five separate in
silico bioinformatics tools (SIFT, PolyPhen, PhyloP,
MutationTaster, and LRT).
CandidateGene/Variant Selection
Candidate genes included genes previously associ-
ated with risk, development or progression of prostate
and/or other cancers as identified through literature
review. Genes involved in DNA damage repair path-
ways were identified through the Gene Ontology (GO)
database and also included as candidates. Additionally,
genes in the 2-LOD support interval of a previously
reported PCa linkage signal on chromosome 17 [9,10]
were included. A total of 695 candidate genes were
included in the analysis (see Supplementary Table). All
SNVs in candidate genes were identified. Nonsense
variants, missense variants that were shared by all
three family members in each family in which they
were observed, and missense variants that were pre-
dicted to be deleterious/conserved by all five predic-
tion programs and were shared by two of three family
members were selected for further analysis.
Variant Verif|cation
All predicted candidate gene nonsense and shared
missense variants were sequenced for verification
using BigDye Terminator v1.1 chemistries on a 3100
Genetic Analyzer (Life Technologies). Confirmed var-
iants were then sequenced in all family members with
DNA available to assess co-segregation with PCa
status.
RESULTS
Eleven hereditary PCa families were selected for
this analysis. Clinical characteristics of families and
individuals sequenced are presented in Table I. All
families described themselves as having European
ancestry and all had between four and eleven con-
firmed PCa cases, with a median of seven PCa cases
per pedigree. Age at PCa diagnosis of the men that
were selected for exome sequencing ranged from 48 to
76 years with a median age of 58 years. Since PCa can
be very clinically heterogeneous, we used a clinical
definition of aggressive PCa (Table I) to assess the
cases. Ten of 33% or 30.3% of sequenced individuals
were classified as clinically aggressive.
Exome sequencing of all 33 men with PCa resulted
in the identification of an average of over 1.4 million
total SNVs per sample (Table II). Within the target
regions, 22,481 coding SNVs including 10,830 missense
and 122 nonsense variants were called on average per
sample.
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Six hundred ninety-seven candidate genes were
identified based on function, location near a previously
reported, chromosome 17 linkage signal, and/or
previous association with PCa or other cancers (see
Supplementary Table). Overall, 4,856 unique SNVs
were identified in candidate genes, including 1,052
missense and 10 nonsense variants (Table II). Seventy-
seven missense variants were shared by all three family
members in each family in which they were observed;
57 of these were observed in all 33 cases and were
presumed to be rare variants in the reference sequence
and excluded from further analysis. Additionally, 59
variants were predicted to be deleterious by each of five
in silico bioinformatics tools. Of the 59 deleterious
variants, 17 were shared by at least two family members
in each family in which they were observed; two of
these were shared by three of three family members and
were included in the shared, missense variants. The
remaining 15 shared, deleterious variants were observed
in two of three family members. All eleven families
sequenced carried at least one nonsense; shared, mis-
sense; or partially shared, deleterious variant.
The 20 shared, missense variants, the 15 partially
shared, deleterious variants and all 10 nonsense
variants (Table III) were sequenced using Sanger
methodology for verification. All 10 nonsense variants
and 33 of 35 missense variants were confirmed. Two
missense variants (ATM Arg189Lys and ATM Ile190-
Lys) were determined to be false positives. Of the
43 confirmed variants, 36 were present in the dbSNP
database, and 7 SNVs were novel. Twenty-six SNVs
were observed in the 1000 genomes European ancestry
samples; those had minor allele frequencies ranging
from 0.1% to 42.1%.
Four missense variants, PARP2 Arg283Gln, BLM
Gln123Arg, LRCC46 Ala295Thr, and KIF2B Pro91Leu,
and 1 nonsense variant, CYP3A43 Arg441Ter, showed
complete co-segregation with PCa status (Fig. 1).
The PARP2 Arg283Gln, BLM Gln123Arg, LRCC46
Ala295Thr, and KIF2B Pro91Leu minor alleles were
observed in the same pedigree, and were carried by
the proband, his affected brother, father and paternal
uncle; none of the minor alleles was carried by the
proband’s mother while the LRCC46 Ala295Thr minor
allele was observed in the proband’s paternal aunt.
The CYP3A43 Arg441Ter minor allele was observed in
a different pedigree where it was carried by two
affected brothers as well as their affected father and
paternal uncle; it was not carried by an unaffected
brother. Twelve additional variants, RAD18 Glu453Ter,
IGHMBP2 Val293Ile, POLE Ala31Ser, RAD51D
Asn138Ser, ASB16 Glu223Gly, HOXB13 Gly84Glu,
B4GALNT2 Tyr274Asn, CHAD Ala342Asp, ANKFN1
Ile443Thr, EGFR Arg962Cys, and POLG Ala467Thr,
exhibited partial co-segregation with PCa status with
TABLEI. Clinical Characteristics of Exome-Sequenced
Families and Individuals
N (%) or median
[range]
Families (N¼ 11)
Number of confirmed affecteds 7 [4–12]
Average age of diagnosis 65.0 [59.4–67.5]
Individuals (N¼ 33)
Age of diagnosis (years) 58 [48–76]
Pre-diagnosis PSA (ng/ml) 5.6 [0.8–38.42]
Gleason gradea
<7 12 (41.4%)
7 14 (48.3%)
>7 3 (10.3%)
Stagea,b
Local 22 (75.9%)
Locally advanced 6 (20.7%)
Metastatic 1 (3.4%)
Clinically aggressive PCac 10 (30.3%)
aNumbers do not add up to 33 due to missing data.
bLocalized¼T1 or T2, N0 and M0 or Pre-Dx PSA <20 ng/ml;
locally advanced¼T3 or T4, N0 and M0 or Pre-Dx PSA >20 ng/
ml but <100 ng/ml; metastatic¼N1 or M1 or Pre-Dx PSA
>100 ng/ml.
cClinically Aggressive PCa¼ (1) Gleason sum >7 or (2) Stage
T3b or T4 or (3) N1 or (4) M1 or (5) pre-diagnosis PSA >15 ng/
ml or (6) Gleason sum¼ 7 and positive margin or (7) Gleason
sum¼ 7 and pre-diagnosis PSA >10 ng/ml.
TABLEII. Summaryof SNVsCalled FromExome
Sequencing
Mean (range)
All called SNVs 1,469,117 (377,621–2,245,788)
SNVs in target region 58,829 (47,205–65,697)
Coding synonymous 11,529 (10,877–11,854)
Missense 10,830 (10,217–11,128)
Nonsense 122 (106–140)
Total N
SNVs in candidate genes 4,856
Synonymous 1,035
Nonsense 10
Missense 1,052
Shareda missense 77
Rare shared missense 20
Deleteriousb 59
Shareda deleterious 2
Partially sharedc deleterious 15
aTo be considered shared, a variant had to be present in all three
family members in each family in which it was observed.
bTo be considered deleterious, a variant had to be predicted to
be damaging or conserved by five of five algorithms used.
cTo be considered partially shared, a variant had to be present in
exactly two family members in each family in which it was
observed.
Candidate Genes in Familial Prostate Cancer 1373
The Prostate
each pedigree containing either one affected non-
carrier or one unaffected carrier of the minor allele.
DISCUSSION
PCa has a well-described heritable component; genes
that are recognized to influence PCa susceptibility
include BRCA1 and BRCA2 [11–18], HOXB13 [5] and
possibly genes associated with the mismatch repair
phenotype [19–21]. In this report, we describe a
candidate gene approach to analyzing whole exome
sequencing data to identify additional hereditary PCa
gene mutations. Our modest sample size (33 PCa cases
from 11 hereditary PCa families) and large number of
TABLEIII. Nonsense and SharedMissenseVariants in Exome SequencingData
Gene Chromosome
Protein
substitution dbSNP ID
No. of
individuals
No. of
families
1000 Genomes
frequency
Nonsense variants
RNASEL 1 Glu265Ter rs74315364 1 1 0.003
RAD18 3 Glu453Ter N/A 3 1 N/A
PARP3 3 Glu373Ter N/A 1 1 N/A
CYP3A43 7 Arg441Ter rs149091175 3 1 N/A
RAD52 12 Ser346Ter rs4987207 3 3 0.016
RAD52 12 Tyr415Ter rs4987208 1 1 0.011
PARP4 13 Leu245Ter N/A 1 1 N/A
RFC3 13 Arg105Ter rs142666536 1 1 N/A
FANCA 16 Gln271Ter rs372163487 1 1 N/A
C17orf57 17 Art211Ter rs71377306 3 2 0.090
Missense variants
GSTM1 1 Lys173Asn rs74837985 6 2 0.421
MSH2 2 Gly322Asp rs4987188 3 1 0.020
PDGFRA 4 Leu221Phe rs139913632 3 1 0.007
UGT2B15 4 Ser172Arg rs200638397 3 1 0.000
IGHMBP2 11 Val293Ile N/A 3 1 N/A
POLE 12 Ala31Ser rs34047482 3 1 0.015
PARP4 13 Ala710Val rs200991879 3 1 0.001
PARP2 14 Arg283Gln rs3093926 3 1 0.073
RAD51B 14 Leu172Trp rs34094401 3 1 0.009
BLM 15 Gln123Arg rs371223446 3 1 N/A
RAD51D 17 Asn138Ser rs201676898 3 1 0.000
ASB16 17 Glu223Gly rs200625323 3 1 0.007
SLC4A1 17 Glu40Lys rs45562031 3 1 0.017
LRRC46 17 Ala295Thr rs145648581 3 1 0.008
HOXB13 17 Gly84Glu rs138213197 3 1 0.003
B4GALNT2 17 Tyr274Asn N/A 3 1 N/A
CHAD 17 Ala342Asp rs144030994 3 1 0.007
KIF2B 17 Pro91Leu rs145539514 3 1 0.003
ANKFN1 17 Ile443Thr rs147516817 3 1 N/A
Deleterious variants
MLH1 3 Lys618Glu rs35001569 2 1 0.005
MLH1 3 Lys618Thr rs63750449 2 1 0.005
PLXNB1 3 Val503Met rs140699424 2 1 N/A
VEGFC 4 Arg61Gln rs41278571 2 1 0.018
EGFR 7 Arg962Cys N/A 2 1 N/A
FANCI 15 Leu605Phe rs117125761 2 1 0.005
POLG 15 Ala467Thr rs113994095 2 1 0.001
RECQL5 17 Arg943His rs200535477 2 1 0.004
XRCC1 19 Ser485Tyr rs2307184 2 1 0.001
WNK4 17 Pro1025Leu rs56099549 4 2 0.013
SLC4A1 17 Val245Met rs148170067 2 1 0.004
SP2 17 Gly497Arg rs143694248 2 1 N/A
KAT7 17 Arg234Thr rs200465294 2 1 N/A
UTP18 17 Tyr535Cys N/A 2 1 N/A
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variants identified led us to focus first on candidate
genes. Examination of SNVs in 697 candidate genes
identified 10 nonsense, 19 shared, and 14 partially
shared, deleterious missense variants in these 11
families. Five variants, CYP3A43 Arg441Ter, PARP2
Arg283Gln, BLM Gln123Arg, LRCC46 Ala295Thr, and
KIF2B Pro91Leu, were shown to completely co-segre-
gate with PCa status. However, given the late onset
nature of PCa and likely incomplete penetrance of
any given PCa gene mutation, all 43 confirmed
mutations are in genes that should be studied in
larger data sets.
When selecting the candidate genes for this analy-
sis, we elected to include all genes within a previously
identified candidate linkage interval at 17q21-22. This
linkage region was first identified by the UM
PCGP [9,10] and later confirmed by several consor-
tium [22]. In 2012, we discovered that mutations in the
HOXB13 gene, a member of the homeobox superfamily
of transcription factors, were associated with the
occurrence of early onset and hereditary PCa [5]. Most
notably, a recurrent non-conservative substitution of
glutamic acid for glycine (Gly84Glu), was found more
commonly in men with early-onset, hereditary PCa
(3.1%) compared to me with late onset-non-familial
PCa (0.6%, P¼ 2.0 106). In our discovery work, four
of 94 unrelated families harbored the HOXB13 Gly84Glu
mutation. When these families were removed and the
remaining 90 families were analyzed together, evidence
for linkage to the chromosome 17q21-22 linkage region
persisted leading us to include all 202 genes in the
linkage region in this current analysis. As proof of
principle supporting the design of our candidate gene
analysis, we identified a single family from the 11 in
which three affected family members shared the
HOXB13 Gly84Glu mutation (Table III).
We identified the CYP3A43 Arg441Ter variant in
four affected members of a single hereditary PCa
family. Overall, this mutation appears to be rare; it
was not observed in the 1000 Genomes data. Although
it was not seen in the Exome Sequencing Project (ESP)
European ancestry (EA) sample; it was observed in 2/
4406 chromosomes of African ancestry in the ESP
database [23]. CYP3A43 Arg441Ter is a protein trun-
Fig. 1. Pedigrees of families with complete co-segregation of a candidate gene variant and PCa status. Red arrows indicated individuals
with exome sequencing data. Plus signs indicate carriers of the variant allele, andminus signs indicate individuals who are wild-type for the
specifiedvariant
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cating mutation resulting in the loss of the final 62
residues of the protein. Although the functional
significance of the variant is unknown, it was pre-
dicted to be damaging by PolyPhen, MutationTaster
and LRT but benign/non-conserved by SIFT and
PhyloP. CYP3A43 is a member of the cytochrome p450
superfamily whose members play roles in drug and
steroid hormone metabolism. The CYP3A43 enzyme,
like other members of this gene family, is involved in
testosterone metabolism [24]. Variants in CYP3A43
have been previously associated with PCa risk and
mortality [25–29], and investigation of the role of
CYP3A43 Arg441Ter in PCa is warranted.
We identified mutations in three PARP genes
(PARP2, PARP3, and PARP4) in hereditary PCa fami-
lies. PARP2 is one of several poly-ADP ribose polymer-
ase genes. The PARP gene products are involved in the
repair of single strand breaks. Additionally, PARP1
and PARP2 germline variants have been associated
with risk of several cancers [30–33], and PARP inhib-
itors have been studied as therapeutic agents in several
cancers [34–36]. PARP2 Arg283Gln was the most
common of the three co-segregating variants we
identified, with a minor allele frequency of 7% in the
1000 genomes database and 6.44% in the ESP EA
sample [23]. PARP2 Arg283Gln was predicted to be
damaging by LRT and conserved by PhyolP but
benign by SIFT, PolyPhen, and Mutation Taster.
A rare, shared missense mutation in the BLM gene
(Gln123Arg) was identified in 1 of 11 PCa families. The
BLM gene encodes a RecQ helicase involved in DNA
damage repair in the homologous recombination (HR)
pathway. Other HR genes, namely BRCA1 and
BRCA2, have previously been associated with PCa
risk [11–18]. Mutations in BLM are known to cause
Bloom syndrome, a recessive disorder with multiple
phenotypic effects including the predisposition to
various cancers [37,38]. Additionally, a BLM truncating
mutation was recently identified as a possible breast
cancer susceptibility allele [39]. BLM Gln123Arg was
not observed in either the dbSNP or 1000 Genomes
databases and was observed in 1 of 8596 EA chromo-
somes in the ESP database. It was predicted to be
benign/non-conserved by five algorithms (SIFT, Poly-
Phen, MutationTaster, LRT, and PhyloP).
In summary, we have used a candidate gene
approach to characterize nonsense, shared missense,
and deleterious mutations shared by at least two
affected family members in a set of hereditary PCa
families. This approach would have led to the identifi-
cation of the HOXB13 Gly84Glu mutation in a heredi-
tary PCa family serving as proof-of-principle for our
study design. Further investigation is needed to deter-
mine the role of the entire set of candidate gene
variants described here in PCa risk and progression.
ACKNOWLEDGMENTS
This work was supported by the National Cancer
Institute Specialized Program of Research Excellence in
Prostate Cancer P50 CA69568 and the International
Consortium for Prostate Cancer Genetics CA89600. The
authors would like to thank all of the PCa patients and
their relatives who participated in this study.
REFERENCES
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA
Cancer J Clin 2013;63(1):11–30.
2. Langeberg WJ, Isaacs WB, Stanford JL. Genetic etiology of
hereditary prostate cancer. Front Biosci 2007;12:4101–4110.
3. Kim ST, Cheng Y, Hsu FC, Jin T, Kader AK, Zheng SL, Isaacs
WB, Xu J, Sun J. Prostate cancer risk-associated variants reported
from genome-wide association studies: Meta-analysis and their
contribution to genetic variation. Prostate 2010;70(16):1729–1738.
4. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J,
Weischer M, Campa D, Riboli E, Key T, Gronberg H, Hunter DJ,
Kraft P, Thun MJ, Ingles S, Chanock S, Albanes D, Hayes RB,
Neal DE, Hamdy FC, Donovan JL, Pharoah P, Schumacher F,
Henderson BE, Stanford JL, Ostrander EA, Sorensen KD, Dork T,
Andriole G, Dickinson JL, Cybulski C, Lubinski J, Spurdle A,
Clements JA, Chambers S, Aitken J, Gardiner RA, Thibodeau
SN, Schaid D, John EM, Maier C, Vogel W, Cooney KA, Park JY,
Cannon-Albright L, Brenner H, Habuchi T, Zhang HW, Lu YJ,
Kaneva R, Muir K, Benlloch S, Leongamornlert DA, Saunders EJ,
Tymrakiewicz M, Mahmud N, Guy M, O’Brien LT, Wilkinson
RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP,
Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N,
Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper
CS, Lophatonanon A, Southey MC, Hopper JL, English DR,
Wahlfors T, Tammela TL, Klarskov P, Nordestgaard BG, Roder
MA, Tybjaerg-Hansen A, Bojesen SE, Travis R, Canzian F, Kaaks R,
Wiklund F, Aly M, Lindstrom S, Diver WR, Gapstur S, Stern
MC, Corral R, Virtamo J, Cox A, Haiman CA, Le Marchand L,
Fitzgerald L, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M,
Meyer A, Serth J, Yeager M, Berndt SI, Marthick JR, Patterson B,
Wokolorczyk D, Batra J, Lose F, McDonnell SK, Joshi AD,
Shahabi A, Rinckleb AE, Ray A, Sellers TA, Lin HY, Stephenson
RA, Farnham J, Muller H, Rothenbacher D, Tsuchiya N, Narita S,
Cao GW, Slavov C, Mitev V, Easton DF, Eeles RA. Seven prostate
cancer susceptibility loci identified by a multi-stage genome-wide
association study. Nat Genet 2011;43(8):785–791.
5. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM,
TembeWD, Wiley KE, Isaacs SD, Johng D, Wang Y, Bizon C, Yan G,
Gielzak M, Partin AW, Shanmugam V, Izatt T, Sinari S, Craig DW,
Zheng SL, Walsh PC, Montie JE, Xu J, Carpten JD, Isaacs WB,
Cooney KA. Germline mutations in HOXB13 and prostate-cancer
risk. N Engl J Med 2012;366(2):141–149.
6. Li H, Durbin R. Fast and accurate short read alignment with
Burrows-Wheeler transform. Bioinformatics 2009;25(14):1754–
1760.
7. DePristo M, Banks E, Poplin R, Garimella K, Maguire J, Hartl C,
Philippakies A. A framework for variation discovery and
genotyping using next-generation DNA sequencing data. Nat
Genet 2011;43:491–498.
8. Wang K, Mingyao L, Hakonarson H, ANNOVAR: Functional
annotation of genetic variants from high-throughput sequencing
data. Nucleic Acids Res 2010;38(16):e164.
1376 Johnson et al.
The Prostate
9. Lange EM, Gillanders EM, Davis CC, Brown WM, Campbell JK,
Jones M, Gildea D, Riedesel E, Albertus J, Freas-Lutz D, Markey C,
Giri V, Dimmer JB, Montie JE, Trent JM, Cooney KA. Genome-
wide scan for prostate cancer susceptibility genes using families
from the University of Michigan prostate cancer genetics project
finds evidence for linkage on chromosome 17 near BRCA1. Prostate
2003;57(4):326–334.
10. Lange EM, Robbins CM, Gillanders EM, Zheng SL, Xu J, Wang Y,
White KA, Chang BL, Ho LA, Trent JM, Carpten JD, Isaacs
WB, Cooney KA. Fine-mapping the putative chromosome 17q
21-22 prostate cancer susceptibility gene to a 10 cM region based
on linkage analysis. Hum Genet 2007;121(1):49–55.
11. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of
cancer in BRCA1-mutation carriers. Breast Cancer Linkage
Consortium. Lancet 1994;343(8899):692–695.
12. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M,
McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of
cancer associated with specific mutations of BRCA1 and BRCA2
among Ashkenazi Jews. N Engl J Med 1997;336(20):1401–1408.
13. Thompson D, Easton DF. Cancer incidence in BRCA1 mutation
carriers. J Natl Cancer Inst 2002;94(18):1358–1365.
14. Douglas JA, Levin AM, Zuhlke KA, Ray AM, Johnson GR,
Lange EM, Wood DP, Cooney KA. Common variation in the
BRCA1 gene and prostate cancer risk. Cancer Epidemiol
Biomarkers Prev 2007;16(7):1510–1516.
15. Agalliu I, Kwon EM, Zadory D, McIntosh L, Thompson J,
Stanford JL, Ostrander EA. Germline mutations in the BRCA2
gene and susceptibility to hereditary prostate cancer. Clin Cancer
Res 2007;13(3):839–843.
16. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P,
Jackson R, Southgate C, Singh R, Falconer A, Dearnaley DP,
Ardern-Jones A, Murkin A, Dowe A, Kelly J, Williams S, Oram
R, Stevens M, Teare DM, Ponder BA, Gayther SA, Easton DF,
Eeles RA. Two percent of men with early-onset prostate cancer
harbor germline mutations in the BRCA2 gene. Am J Hum Genet
2003;72(1):1–12.
17. Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C,
Gulati T, Wadsworth E, Donat S, Robson ME, Ellis NA, Offit K.
BRCA mutations and risk of prostate cancer in Ashkenazi Jews.
Clin Cancer Res 2004;10(9):2918–2921.
18. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E,
Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I,
Wong B, Narod SA. Prevalence and penetrance of germline
BRCA1 and BRCA2 mutations in a population series of 649
women with ovarian cancer. Am J Hum Genet 2001;68(3):
700–710.
19. Bauer CM, Ray AM, Halstead-Nussloch BA, Dekker RG,
Raymond VM, Gruber SB, Cooney KA. Hereditary prostate
cancer as a feature of Lynch syndrome. Fam Cancer 2011;10(1):
37–42.
20. Raymond VM, Mukherjee B, Wang F, Huang SC, Stoffel EM,
Kastrinos F, Syngal S, Cooney KA, Gruber SB. Elevated risk of
prostate cancer among men with Lynch syndrome. J Clin Oncol
2013;31(14):1713–1718.
21. Ryan S, Jenkins MA, Win AK. Risk of prostate cancer in Lynch
syndrome: A systematic review and meta-analysis. Cancer
Epidemiol Biomarkers Prev 2014;23(3):437–449.
22. Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA,
Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hooper
JL, Mahle L, Moller P, Bishop T. A combined genomewide
linkage scan of 1233 families for prostate cancer-susceptibility
genes conducted by the international consortium for prostate
cancer genetics. Am J Hum Genet 2005;77(2):219–229.
23. Exome Variant Server, NHLBI GO Exome Sequencing Project
(ESP), Seattle, WA (URL: http://evs.gs.washington.edu/EVS/).
24. Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG. cDNA
cloning and initial characterization of CYP3A43, a novel human
cytochrome P450. Mol Pharmacol 2001;59(2):386–392.
25. Siemes C, Visser LE, de Jong FH, Coebergh JW, Uitterlinden AG,
Hofman A, Stricker BH, van Schaik RH. Cytochrome P450 3A
gene variation, steroid hormone serum levels and prostate
cancer—The Rotterdam study. Steroids 2010;75(12):1024–1032.
26. Rebbeck TR, Rennert H, Walker AH, Panossian S, Tran T,
Walker K, Spangler E, Patacsil-Coomes M, Sachdeva R, Wein AJ,
Malkowicz SB, Zeigler-Johnson C. Joint effects of inflammation
and androgen metabolism on prostate cancer severity. Int J
Cancer 2008;123(6):1385–1389.
27. Stone A, Ratnasinghe LD, Emerson GL, Modali R, Lehman T,
Runnells G, Carroll A, Carter W, Barnhart S, Rasheed AA,
Greene G, Johnson DE, Ambrosone CB, Kadlubar FF, Lang NP.
CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in
African Americans and Caucasians. Cancer Epidemiol Biomark-
ers Prev 2005;14(5):1257–1261.
28. Zeigler-Johnson C, Friebel T, Walker AH, Wang Y, Spangler E,
Panossian S, Patacsil M, Aplenc R, Wein AJ, Malkowicz SB,
Rebbeck TR. CYP3A4, CYP3A5, and CYP3A43 genotypes and
haplotypes in the etiology and severity of prostate cancer.
Cancer Res 2004;64(22):8461–8467.
29. Zeigler-Johnson CM, Walker AH, Mancke B, Spangler E, Jalloh M,
McBride S, Deitz A, Malkowicz SB, Ofori-Adjei D, Gueye SM,
Rebbeck TR. Ethnic differences in the frequency of prostate
cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered
2002;54(1):13–21.
30. Pabalan N, Francisco-Pabalan O, Jarjanazi H, Li H, Sung L,
Ozcelik H. Racial and tissue-specific cancer risk associated with
PARP1 (ADPRT) Val762Ala polymorphism: A meta-analysis.
Mol Biol Rep 2012;39(12):11061–11072.
31. Li Y, Li S, Wu Z, Hu F, Zhu L, Zhao X, Cui B, Dong X, Tian S,
Wang F, Zhao Y. Polymorphisms in genes of APE1, PARP1, and
XRCC1: Risk and prognosis of colorectal cancer in a Northeast
Chinese population. Med Oncol 2013;30:505.
32. Popanda O, Seibold P, Nikolov I, Oakes CC, Burwinkel B,
Hausmann S, Flesch-Janys D, Plass C, Chang-Claude J,
Schmezer P. Germline variants of base excision repair genes and
breast cancer: A polymorphism in DNA polymerase gamma
modifies gene expression and breast cancer risk. Int J Cancer
2013;132(1):55–62.
33. Li C, Hu Z, Lu J, Liu Z, Wang L-E, El-Naggar AK, Sturgis EM,
Spitz MR, Wei Q. Genetic polymorphisms in DNA base-excision
repair genesADPRT, XRCC1, and APE1 and the risk of squa-
mous cell carcinoma of the head and neck. Cancer 2007;110(4):
867–875.
34. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M,
Mortimer P, Swaisland H, Lau A, O’Connor MJ, Ashworth A,
Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of
poly(ADP-ribose) polymerase in tumors from BRCA mutation
carriers. N Engl J Med 2009;361(2):123–134.
35. Sandhu SK, Yap TA, de Bono JS. Poly(ADP-ribose) polymerase
inhibitors in cancer treatment: A clinical perspective. Eur J
Cancer 2010;46(1):9–20.
36. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M,
Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A’Hern R,
Candidate Genes in Familial Prostate Cancer 1377
The Prostate
Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH,
de Bono JS, Kaye SB. Poly(ADP)-ribose polymerase inhibition:
Frequent durable responses in BRCA carrier ovarian cancer
correlating with platinum-free interval. J Clin Oncol 2010;28(15):
2512–2519.
37. German J, Roe AM, Leppert MF, Ellis NA. Bloom syndrome: An
analysis of consanguineous families assigns the locus mutated to
chromosome band 15q26.1. Proc Natl Acad Sci USA 1994;
91(14):6669–6673.
38. German J, Sanz MM, Ciocci S, Ye TZ, Ellis NA. Syndrome-
causing mutations of the BLM gene in persons in the Bloom’s
Syndrome Registry. HumMutat 2007;28(8):743–753.
39. Horwitz MS, Thompson ER, Doyle MA, Ryland GL, Rowley SM,
Choong DYH, Tothill RW, Thorne H, Barnes DR, Li J, Ellul J,
Philip GK, Antill YC, James PA, Trainer AH, Mitchell G, Camp-
bell IG. Exome sequencing identifies rare deleterious mutations
in DNA repair genes FANCC and BLM as potential breast cancer
susceptibility alleles. PLoS Genet 2012;8(9):e1002894.
SUPPORTINGINFORMATION
Additional supporting information may be found in the
online version of this article at the publisher’s web-site.
1378 Johnson et al.
The Prostate
